Chemistry:Nelotanserin

From HandWiki
Short description: Chemical compound
Nelotanserin
Nelotanserin structure.png
Clinical data
Other namesAPD-125
Routes of
administration		Oral
ATC code
  • none
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC18H15BrF2N4O2
Molar mass437.245 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Nelotanserin (former developmental code name APD-125) is a drug developed by Arena Pharmaceuticals which acts as an inverse agonist on the serotonin receptor subtype 5-HT2A and was under development for the treatment of insomnia.[1] It was shown to be effective and well tolerated in clinical trials,[2][3] but development was halted in December 2008 because the substance did not meet the trial's effectiveness endpoints.[4] Research continues on newer analogues which may potentially be more successful.[5]

Later, nelotanserin was repurposed for the treatment of Lewy body dementia (LBD) by Axovant Sciences (now Sio Gene Therapies).[6] In late 2018, the company announced that while nelotanserin was generally well-tolerated by LBD patients in a small Phase 2 clinical trial for the treatment of REM sleep behavior disorder (RBD) and there were positive indications on some secondary trial outcomes such as sleep diaries and some polysomnogram sleep parameters, the drug failed to meet its primary endpoint of reducing the frequency of RBD episodes and would be discontinued.[7]

References

  1. ↑ "Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia". Journal of Medicinal Chemistry 53 (5): 1923–36. March 2010. doi:10.1021/jm9007328. PMID 20143782. 
  2. ↑ "APD125, a selective serotonin 5-HT(2A) receptor inverse agonist, significantly improves sleep maintenance in primary insomnia". Sleep 31 (12): 1663–71. December 2008. doi:10.1093/sleep/31.12.1663. PMID 19090322. 
  3. ↑ "Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia". The Journal of Pharmacology and Experimental Therapeutics 332 (1): 281–90. January 2010. doi:10.1124/jpet.109.160994. PMID 19841476. 
  4. ↑ "APD125 for Insomnia". Arena Pharmaceuticals, Inc.. http://www.arenapharm.com/wt/page/apd125.html. 
  5. ↑ "Synthesis and in vivo evaluation of phenethylpiperazine amides: selective 5-hydroxytryptamine(2A) receptor antagonists for the treatment of insomnia". Journal of Medicinal Chemistry 53 (15): 5696–706. August 2010. doi:10.1021/jm100479q. PMID 20684606. 
  6. ↑ "Nelotanserin - Axovant Gene Therapies". Adis International Ltd.. Springer Science+Business Media. http://adisinsight.springer.com/drugs/800021795. 
  7. ↑ "Axovant Reports Results of Exploratory Phase 2 Clinical Study of Nelotanserin in Lewy Body Dementia Patients Experiencing REM Sleep Behavior Disorder". Sio Gene Therapies. December 10, 2018. https://investors.siogtx.com/news-releases/news-release-details/axovant-reports-results-exploratory-phase-2-clinical-study. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Nelotanserin&oldid=3324302"